Preclinical evaluation of high-dose Griffithsin carrageenan fast-dissolving insert for HIV, HSV-2, and HPV prevention
Microbiology Spectrum · 02.06.2026 · 14 (6)
DOI: 10.1128/spectrum.01966-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 02.06.2026. Verfasst von J A Fernández Romero und 14 weiteren Autor:innen. Beteiligte Einrichtung: Science Department, Borough of Manhattan Community College, The City University of New York, New York, New York, USA. Hauptthemen laut MEDLINE: Carrageenan, Plant Lectins, Antiviral Agents, Papillomavirus Infections. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, U.S. Agency for International Development.
Abstract (Originalsprache)
Griffithsin (GRFT) is an antiviral lectin that blocks human immunodeficiency virus (HIV) entry. When combined with carrageenan (CG), GRFT has strong activity against herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV). We conducted a preclinical evaluation of a high-dose vaginal fast-dissolving insert (FDI) containing 3 mg GRFT—equivalent to 3× the clinical dose—and compared it with a 1 mg formulation. Studies included FDI disintegration (macaques, rabbits); GRFT pharmacokinetics, pharmacodynamics, and inflammatory response (macaques); toxicity (rats); and immunogenicity (macaques, rats). Disintegration times varied between species, emphasizing the importance of evaluating this parameter in humans. In macaques, cervico-vaginal lavage (CVL) GRFT concentrations exceeded levels associated with in vivo efficacy 12 h after administration of the 3 mg GRFT/CG FDI. Potent anti-HIV1 BaL activity was detected in CVLs collected 24 h following the 3 mg dose and 12 h after the 1 mg dose. CVLs inhibited HSV-2 at 4 h and HPV at 12 h after both GRFT doses. GRFT/CG FDIs caused no inflammatory response and did not alter vaginal pH. In rats, repeated daily dosing at up to 10× the clinical dose revealed no safety concerns. Although anti-drug antibodies (ADAs) developed in macaques and rats, systemic GRFT was undetectable, suggesting that ADAs are unlikely to alter pharmacokinetics. Overall, the CVL GRFT concentrations and anti-HIV activity following administration of 3 mg GRFT/CG FDIs suggest a longer protection window—at least 12 h—against HIV-1 compared with the 1 mg FDI, and both formulations demonstrate activity against HSV-2 and HPV. These findings support continued GRFT/CG FDI development. IMPORTANCE There is an undeniable need to develop multipurpose prevention products that simultaneously protect against human immunodeficiency virus (HIV) and other sexually transmitted pathogens. To that end, we conducted a preclinical evaluation of a carrageenan-based fast-dissolving vaginal insert containing 3 mg of anti-viral lectin Griffithsin—equivalent to 3× clinical dose—and compared it with a 1 mg insert. Both formulations were safe and demonstrated potent anti-HIV, herpes simplex virus type 2 (HSV-2), and human papillomavirus (HPV) activity. Our data suggest that a 3× clinical dose Griffithsin formulation may afford an extended window of protection against HIV compared to the 1× dose formulation. These data support further development and clinical testing of high-dose Griffithsin carrageenan fast-dissolving vaginal insert.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Science Department, Borough of Manhattan Community College, The City University of New York, New York, New York, USA.
- Center for Biomedical Research, Population Council, New York, New York, USA.
- NIH-Maximizing Access to Research Careers at Brooklyn College, New York, New York, USA.
- Tulane National Primate Research Center, Covington, Louisiana, USA.
ORCID-Profile: L B Haddad, N Teleshova
Förderung
- NIH HHS
- U.S. Agency for International Development
Zitieren
APA
Fernández Romero, J. A., Barnable, P., Visciano, M. L., Aravantinou, M., Meyer, A., Grecky, S., Schiro, F., Grasperge, B., Gadsden, J., Kommineni, N., Angsantikul, P., Kumar, N., Nuttall, J., Haddad, L. B., & Teleshova, N. (2026). Preclinical evaluation of high-dose Griffithsin carrageenan fast-dissolving insert for HIV, HSV-2, and HPV prevention. Microbiology Spectrum, 14(6). https://doi.org/10.1128/spectrum.01966-25
Vancouver
Fernández Romero JA, Barnable P, Visciano ML, Aravantinou M, Meyer A, Grecky S, et al. Preclinical evaluation of high-dose Griffithsin carrageenan fast-dissolving insert for HIV, HSV-2, and HPV prevention. Microbiology Spectrum. 2026;14(6). doi:10.1128/spectrum.01966-25
BibTeX
@article{FernndezRomero2026,
author = {Fernández Romero, J A and Barnable, P and Visciano, M L and Aravantinou, M and Meyer, A and Grecky, S and Schiro, F and Grasperge, B and Gadsden, J and Kommineni, N and Angsantikul, P and Kumar, N and Nuttall, J and Haddad, L B and Teleshova, N},
title = {Preclinical evaluation of high-dose Griffithsin carrageenan fast-dissolving insert for HIV, HSV-2, and HPV prevention},
journal = {Microbiology Spectrum},
year = {2026},
volume = {14},
number = {6},
doi = {10.1128/spectrum.01966-25}
}
EUVIMED